- RecruitingPHASE3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
This study looks at a new medicine called BGB-43395 combined with letrozole for advanced breast cancer. It compares this new combination to standard treatments (other CDK4/6 inhibitors plus letrozole) for people who haven't had previous treatment for their advanced cancer.
For: HR+/HER2- Breast CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.
For: Breast CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
This study looks at a new combination treatment for advanced breast cancer that's hormone-positive and HER2-negative. It combines a new drug called capivasertib with existing treatments to see if it works better at slowing down the cancer's growth.
For: Locally Advanced (Inoperable) or Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
This study is testing a new drug, AZD9833, for advanced breast cancer. It's for people whose cancer has a specific gene change (ESR1 mutation) and are already on certain treatments. Researchers want to see if adding AZD9833 works better than current medicines.
For: ER-Positive HER2-Negative Breast CancerUnited States · Australia · Austria - Active not recruitingPHASE3
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
This study looks at a new drug, abemaciclib, combined with standard treatment for prostate cancer that has spread. We want to see if this combination can stop the cancer from getting worse for longer in men whose cancer is still responding to hormone therapy.
For: Prostatic Neoplasms · Neoplasm Metastasis · Urogenital NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
For: Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
This study is for people with advanced breast cancer that has a specific genetic change (PIK3CA). It's testing a new drug, Tersolisib, alongside other cancer medicines, to see if it's safe and helps treat the disease effectively.
For: Breast Neoplasms · Neoplasm MetastasisUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - RecruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
For: Advanced Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This study is looking at a new drug, camizestrant, for people with a common type of early breast cancer. It aims to see if camizestrant, compared to usual hormone therapy, can better prevent the cancer from coming back.
For: Breast Cancer, Early Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
This study is looking at a new drug, PF-07220060, combined with letrozole for advanced breast cancer. It compares this new treatment to existing approved therapies to see if it's safe and works well for people whose cancer needs hormones to grow.
For: Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
This study is looking into a new medicine, LOXO-783, for breast cancer and other solid tumours with a specific gene change (PIK3CA). It aims to understand if the medicine is safe, what side effects it has, and how well it works.
For: Breast CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
This study is testing a new drug, giredestrant, against a standard treatment for advanced breast cancer. It's for people whose cancer has grown resistant to previous hormone therapy, to see if giredestrant, combined with other drugs, works better and is safe.
For: Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
This study looks at new treatments for HR-positive/HER2-negative breast cancer that has been surgically removed. It uses blood tests to find tiny traces of cancer that might come back. If found, patients may get new drug combinations to see if they can stop the cancer from returning.
For: Breast CancerSpain · United Kingdom - Active not recruitingPHASE3
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
This study for advanced ER+, HER2- breast cancer tests a new drug called imlunestrant. Researchers want to see if it works better than standard hormone therapy, and if adding abemaciclib helps even more. It aims to find better treatments for this common type of breast cancer.
For: Breast Neoplasms · Neoplasm MetastasisUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
This study is testing a new combination of treatments, abemaciclib and tamoxifen, or abemaciclib alone, for women with advanced breast cancer that has spread. It aims to see if these treatments are safe and effective for patients who have already had previous therapies.
For: Metastatic Breast CancerUnited States · Argentina · Austria - Active not recruitingPHASE2, PHASE3
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
This study is looking at a new combination of medicines, abemaciclib, abiraterone acetate, and prednisone, for men with advanced prostate cancer that has spread. It aims to see if adding abemaciclib is safe and effective in treating their cancer.
For: Prostate CancerUnited States · Australia · China - RecruitingPHASE1, PHASE2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
This study looks at new drug combinations (Elacestrant and Abemaciclib) for people with breast cancer that has spread to the brain. It aims to find the right dose and see how well the new combination works for ER-positive, HER-2 negative breast cancer.
For: Breast Neoplasms · Brain Neoplasms · Neoplasms by SiteUnited States · Belgium · France - RecruitingPHASE1, PHASE2
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
This study looks at a new drug, AZD8421, for advanced breast cancer (ER+ HER2- type) and a type of ovarian cancer. It checks how safe and effective it is, sometimes alone and sometimes with other cancer medicines.
For: ER+ HER2- Advanced Breast Cancer · High-grade Serous Ovarian Cancer (HGSOC)United States · Australia · South Korea - Active not recruitingPHASE3
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
This study looks at a new way to treat breast cancer in post-menopausal women. It tests if adding a drug called abemaciclib to standard hormone therapy can better stop the cancer from coming back after surgery, especially for those at higher risk.
For: Breast Cancer FemaleUnited Kingdom - RecruitingPHASE1, PHASE2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
This study is looking at new treatments for advanced breast cancer. It tests a new drug called GDC-4198, alone or with giredestrant, and compares it to another combination (abemaciclib + giredestrant). The aim is to find safer and more effective ways to treat this type of cancer.
For: Breast CancerUnited States · Australia · Brazil - Active not recruitingPHASE1
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
This study looks at a new combination of medicines, abemaciclib and pembrolizumab, for people with advanced non-small cell lung cancer or a specific type of breast cancer. It aims to see how safe and effective these treatments are together.
For: Non Small Cell Lung Cancer · Breast CancerUnited States · Belgium · France - Active not recruitingPHASE3
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
This study looks at new ways to treat advanced breast cancer that is sensitive to hormones and doesn't have too much HER2 protein. It compares a new drug called abemaciclib plus fulvestrant to fulvestrant alone, to see which helps patients live longer without their cancer growing.
For: Breast NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
This study looks at a medicine called abemaciclib for people in the UK with a certain type of advanced lung cancer (non-small cell lung cancer) that has a specific gene change (KRAS mutation) and has come back after other treatments. It aims to see how safe and effective abemaciclib is.
For: Non Small Cell Lung CancerUnited States · Argentina · Austria - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
For: Ovarian CancerUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
This study is testing a new medicine called EP0062 for advanced breast cancer. It aims to find the safest and most effective dose, both alone and with other standard treatments, for women whose cancer has specific features.
For: Hormone Receptor-positive Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Metastatic Breast CancerUnited States · Spain · United Kingdom - Active not recruitingPHASE1, PHASE2
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
This study is testing a new drug called elacestrant with other breast cancer medicines. It's for people with a specific type of advanced breast cancer that has spread. The main goals are to see if these drug combinations are safe and if they can help shrink the cancer.
For: Breast Cancer · Metastatic Breast CancerUnited States · Argentina · Australia - RecruitingPHASE2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
This study is a research programme looking at new ways to treat cancer in children and young adults aged 1 to 39. It tests different medicines to find out how well they work and if they are safe.
For: Neoplasms · Child · AdolescentUnited States · Australia · Belgium